call 1800 257 600 email [email protected]

PTEN Hamartoma Tumour Syndrome

PTEN hamartoma tumour syndrome (PHTS) is a group of genetic conditions that causes the development of multiple benign (non-cancerous) and malignant (cancerous) tumours throughout the body. It is caused by a mutation of the phosphatase and tensin homolog (PTEN) gene, which is a tumour suppressor gene located on chromosome 10.

Familial cancer syndromes, also known as hereditary cancer syndromes, are rare conditions that cause an increased risk of cancer as the result of inherited genetic mutations in certain cancer-related genes. They can affect both adults and children, however they generally develop in people at a younger age than normal. While familial cancer syndromes are not classified as cancer, they are equally as severe and can be life-threatening as they are associated with the development of various tumours throughout the body. Having a familial cancer syndrome does not guarantee the development of cancer, however the risk of developing cancer is higher than those who do not have a familial cancer syndrome.

PHTS tends to affect the sexes equally, and is generally diagnosed between the ages of 30-50. However, anyone can develop this disease.

Types of PTEN Hamartoma Syndrome

There are four types of PHTS, which are characterised by tumour locations and disease characteristics.

Cowden Syndrome

Cowden syndrome, also known as multiple hamartoma syndrome, is the most common subtype of PHTS, and is associated with the development of malignancies – most commonly breast, thyroid and kidney cancers – as well as other benign growths. For more information on Cowden syndrome, please refer to the Rare Cancers Australia Cowden Syndrome page.

Bannayan-Riley-Ruvalcaba Syndrome (BRRS)

Bannayan-Riley-Rubalcaba syndrome (BRRS), also known as Bannayan-Zonana syndrome, Ruvalcaba-Myhre syndrome and Riley-Smith syndrome, is a less common variant on PHTS that is often diagnosed in early childhood. It is characterised by a large head size (macrocephaly), dark freckle-like spots on the penis in males and multiple benign growths. While the likelihood of people with BRRS developing cancer is not well understood, it is recommended that people with the disease have regular check-ups to monitor for any signs of malignancy.

Proteus Syndrome

Proteus syndrome (PS), also known as elattoproteus syndrome and elephant man disease, is a rare subtype of PHTS that is often diagnosed in childhood. It is characterised by abnormal bone and blood vessel growth, multiple skin lesions, multiple benign growths, and overgrowth of different body parts over time. While the likelihood of people with PS developing cancer is not well understood, it is recommended that people with the disease have regular check-ups to monitor for any signs of malignancy.

Proteus-like Syndrome

Proteus-like syndrome is a rare subtype of PHTS that describes patients who do not meet the diagnostic criteria for PS, but have many of the characteristics of the disease associated with the condition. Similarly to PS, it is generally diagnosed in childhood and may exhibit some of the same symptoms – including abnormal bone and blood vessel growth, multiple skin lesions and multiple benign growths. While the likelihood of people with Proteus-like syndrome developing cancer is not well understood, it is recommended that people with the disease have regular check-ups to monitor for any signs of malignancy.

Types of Tumours Associated with PTEN Hamartoma Syndrome

PHTS may result in the development of some of the following:

Treatment

When cancers are detected, they are staged and graded based on size, metastasis (whether the cancer has spread to other parts of the body) and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you. However, each patient with PHTS will present with a unique disease behaviour, with varying cancer locations and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease. Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Type of cancer present.
  • Cancer location.
  • Whether or not the cancer has metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may also recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment options for tumours associated with PHTS may include:

  • Surgery to remove as much of the tumour(s) as possible – these will vary based on tumour type and location.
  • Chemotherapy.
  • Radiation therapy.
  • Targeted therapy.
  • Immunotherapy.
  • Watch and wait.
  • Hormone therapy.
  • Clinical trials.
  • Palliative care.

Cancer Screening

Once a diagnosis of PHTS has been confirmed, implementing a targeted screening plan becomes essential due to the increased risk of developing certain cancers.  The content of this plan will vary from person to person based on the genetic mutation involved, your family’s history of cancer and the types of cancers that may be present. It will also outline the routine tests you should have and how regularly you should have them.  Some recommendations for PHTS may include:

  • Annual physical exam starting at 18 years, or five years before the age of the first relevant cancer diagnosis in the family (whichever comes first).
  • Clinical breast exam every 6-12 months in females starting at age 25.
  • Annual mammogram in females starting at 30-35 – breast MRI should also be considered.
  • Annual thyroid ultrasound from time of diagnosis.
  • Annual ultrasound every 1-2 years starting at age 40 – MRI or CT scan can also be considered.
  • Transvaginal ultrasound in post-menopausal females as needed.
  • Colonoscopy every five years starting at age 35, or more frequently if symptomatic or if polyps have been found.
  • Annual skin examinations.

Screening options for PHTS may evolve as new technologies are developed and our understanding of the condition grows. It is essential to discuss your individual circumstances with your healthcare team to determine the most appropriate screening plan for you.

Risk factors

PHTS is caused by a genetic mutation of the phosphatase and tensin homolog (PTEN) gene, which is a type of tumour suppressor gene. For patients with Cowden syndrome, two other genes, KLLN and WPP1, may also cause the disease in some families. PHTS are autosomal dominant diseases, which means you have a 50% chance of inheriting the condition if one of your parents carries the mutation.

Symptoms

The symptoms of PHTS often vary by the type(s) of tumours present. General symptoms of PHTS may include:

  • Hamartomas.
  • Trichilemmomas (benign, wart-like growths that start in the hair follicles).
  • Oral papules or fibromas.
  • Keratoses on the surfaces of the hands and feet.
  • Macrocephaly.
  • Intellectual disability.
  • Thyroid abnormalities, such as benign tumours and goitres.
  • Testicular lipomatosis.
  • Lipomas.
  • Polyps in the gastrointestinal tract.
  • Fibromas.
  • Dark freckle-like spots on the penis in males.
  • Vascular anomalies (abnormalities with blood vessels).
  • Intramuscular lesions.
  • Muscle weakness.
  • High-arched palate of the mouth.
  • Abnormal range of motion of joints, also known as joint hypermobility.
  • Haemangiomas.
  • Overgrowths of cells on the face.
  • Low muscle tone (hypotonia).
  • Seizures (less common).
  • Autism spectrum disorder (ASD).
  • Funnel chest.
  • Abnormalities of the spine, potentially including scoliosis, kyphosis, or kyphoscoliosis.

Symptoms related to specific tumours can be found on our knowledgebase.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have tumours associated with PHTS, they may order some of the following tests to confirm the diagnosis and refer you to a specialist for treatment. The tests required for diagnosis will often vary based on the symptoms present, and where the tumour(s) are suspected to be located.

  • Physical examination.
  • Genetic testing.
  • Pelvic examination.
  • Neurological examination.
  • Blood tests.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
    • Ultrasound.
  • Exploratory procedures, such as an endoscopy.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.